+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Uveitis - Pipeline Review, H1 2020

  • ID: 5017451
  • Drug Pipelines
  • March 2020
  • Region: Global
  • 259 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Aciont Inc
  • Apitope International NV
  • Eli Lilly and Co
  • Galapagos NV
  • Mitotech SA
  • Orchid Pharma Ltd
  • MORE
Uveitis - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Uveitis - Pipeline Review, H1 2020, provides an overview of the Uveitis (Ophthalmology) pipeline landscape.

Uveitis is swelling and irritation of the uvea, the middle layer of the eye. Uveitis can affect one or both eyes. Uveitis can be caused by autoimmune disorders such as rheumatoid arthritis or ankylosing spondylitis, infection, or exposure to toxins. Symptoms include blurred vision, dark, floating spots in the vision, eye pain, redness of the eye and sensitivity to light. The predisposing factors include having an infection, an autoimmune or inflammatory disorder and history of eye injury. Treatment includes steroid eye drops, anti-inflammatory and antibiotic or antiviral medication.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Uveitis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Uveitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Uveitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Uveitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages are 1, 3, 9, 6, 1, 1, 38 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Uveitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Uveitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Uveitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Uveitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Uveitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Uveitis (Ophthalmology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Uveitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Uveitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Aciont Inc
  • Apitope International NV
  • Eli Lilly and Co
  • Galapagos NV
  • Mitotech SA
  • Orchid Pharma Ltd
  • MORE
  • Introduction
  • Uveitis - Overview
  • Uveitis - Therapeutics Development
  • Uveitis - Therapeutics Assessment
  • Uveitis - Companies Involved in Therapeutics Development
  • Uveitis - Drug Profiles
  • Uveitis - Dormant Projects
  • Uveitis - Discontinued Products
  • Uveitis - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Uveitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Uveitis - Pipeline by Aciont Inc, H1 2020
  • Uveitis - Pipeline by Active Biotech AB, H1 2020
  • Uveitis - Pipeline by Acucela Inc, H1 2020
  • Uveitis - Pipeline by Akari Therapeutics Plc, H1 2020
  • Uveitis - Pipeline by Aldeyra Therapeutics Inc, H1 2020
  • Uveitis - Pipeline by Alvotech ehf, H1 2020
  • Uveitis - Pipeline by Apidel SA, H1 2020
  • Uveitis - Pipeline by Apitope International NV, H1 2020
  • Uveitis - Pipeline by Bonac Corp, H1 2020
  • Uveitis - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Uveitis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2020
  • Uveitis - Pipeline by Dobecure SL, H1 2020
  • Uveitis - Pipeline by E&B Technologies LLC, H1 2020
  • Uveitis - Pipeline by Elasmogen Ltd, H1 2020
  • Uveitis - Dormant Projects, H1 2020
  • Uveitis - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Uveitis, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aciont Inc
  • Active Biotech AB
  • Acucela Inc
  • Akari Therapeutics Plc
  • Aldeyra Therapeutics Inc
  • Alvotech ehf
  • Apidel SA
  • Apitope International NV
  • Bonac Corp
  • Bristol-Myers Squibb Co
  • Chugai Pharmaceutical Co Ltd
  • Dobecure SL
  • E&B Technologies LLC
  • Elasmogen Ltd
  • Eleusis Ltd
  • Eli Lilly and Co
  • Emerald Bioscience Inc
  • EnhanX Biopharm Inc
  • Enzo Biochem Inc
  • EyePoint Pharmaceuticals Inc
  • Eyevensys SAS
  • EyGen Ltd
  • F. Hoffmann-La Roche Ltd
  • Galapagos NV
  • HanAll Biopharma Co Ltd
  • HanAll Biopharma Co Ltd
  • Idogen AB
  • InSight Biopharmaceuticals Ltd
  • Kodiak Sciences Inc
  • Kv1.3 Therapeutics
  • MetrioPharm AG
  • Mitotech SA
  • Naegis Pharmaceuticals Inc
  • NeuClone Pty Ltd
  • Novaliq GmbH
  • Novartis AG
  • Oculis SA
  • OKYO Pharma Ltd
  • OncoNOx ApS
  • Orchid Pharma Ltd
  • OSE Immunotherapeutics
  • Palatin Technologies Inc
  • Panag Pharma Inc
  • Panoptes Pharma GesmbH
  • Pharmapraxis
  • Re-Pharm Ltd
  • RiniSight Inc
  • Ripple therapeutics Corp
  • Santen Pharmaceutical Co Ltd
  • SFA Therapeutics LLC
  • Tarsius Pharma Ltd
  • Tianjin Pharmaceuticals Group Co Ltd
  • Vyome Therapeutics Inc
Note: Product cover images may vary from those shown
Adroll
adroll